In its 80 year history Allergy Therapeutics has emerged as both a leader and pioneer in specific immunotherapy, contributing to numerous important developments in the research, development and manufacturing of allergen extracts.  The company has become a hallmark of quality and innovation in specific immunotherapy.

In 1999, Allergy Therapeutics revolutionised specific immunotherapy by introducing an innovative ultra-short course allergy vaccine (just 4 injections/year for 3 years) which is formulated with TLR-4 agonist, monophosphoryl lipid A (MPL®). Allergy Therapeutics are using this modern therapy concept as the basis for the development of a future generation of specific immunotherapies.

To learn more about the history of Allergy Therapeutics, the discovery of the mechanism of allergy and the development of specific-immunotherapy please contact us here.